Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials

Highlights • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2015-11, Vol.51 (17), p.2615-2623
Hauptverfasser:	Duffaud, F, Sleijfer, S, Litière, S, Ray-Coquard, I, Le Cesne, A, Papai, Z, Judson, I, Schöffski, P, Chawla, S.P, Dewji, R, Marreaud, S, Verweij, J, van der Graaf, W.T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biomarker Blood Pressure - drug effects Blood Pressure - physiology Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Disease-Free Survival Europe Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Hypertension Hypertension - chemically induced Hypertension - physiopathology Male Middle Aged Outcome Assessment (Health Care) - methods Outcome Assessment (Health Care) - statistics & numerical data Pazopanib Proportional Hazards Models Prospective Studies Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Retrospective Studies Sarcoma Sarcoma - drug therapy Sulfonamides - adverse effects Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment are needed. • Hypertension (HTN) is a specific side-effect of pazopanib. • In 337 patients the association of occurrence of HTN and outcome was assessed. • No association was found between the occurrence of HTN and outcome.
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2015.08.002